InspireMD, Inc. (NSPR) intrinsic value & 10-year financials
InspireMD, Inc. (NSPR) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 18.9% a year to $9.0M, with an average return on invested capital of -260.5%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.46
- Market cap
- $29.3M
- Revenue (FY2025)
- $9.0M
- Revenue growth (10-yr CAGR)
- 18.9%
- ROIC (10-yr avg)
- -260.5%
- Free cash flow (FY2025)
- -$36.8M
NSPR 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $9.0M | -$48.8M | -$0.76 | -$36.8M | -552.6% | -147.1% |
| FY2024 | $7.0M | -$32.0M | -$0.76 | -$23.3M | -478.0% | -134.4% |
| FY2023 | $6.2M | -$19.9M | -$0.82 | -$16.8M | -340.7% | -94.3% |
| FY2022 | $5.2M | -$18.5M | -$0.78 | -$16.0M | -361.9% | -103.2% |
| FY2021 | $4.5M | -$14.9M | — | -$13.6M | -327.4% | -128.9% |
| FY2020 | $2.5M | -$10.5M | — | -$9.2M | -417.7% | -1998.1% |
| FY2019 | $3.7M | -$10.0M | — | -$10.1M | -263.8% | -1880.5% |
| FY2018 | $3.6M | -$7.2M | — | -$7.7M | -211.4% | -126.0% |
| FY2017 | $2.8M | -$8.4M | — | -$8.4M | -298.2% | 1040.7% |
| FY2016 | $1.9M | -$8.5M | — | -$7.5M | -403.8% | 966.9% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
InspireMD, Inc. is a consistent compounder, expanding top-line revenue at 18.9% annually over the past decade.
InspireMD, Inc. has historically struggled to out-earn its cost of capital, averaging just -75.3% ROIC.
InspireMD, Inc. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, InspireMD, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-25.24 per share.